AbbVie Inc. (ABBV) Research & Development Expenses
The r&d expense for AbbVie Inc. (ABBV) is $9.10 Billion with a year-over-year change of -28.89%. Research and Development (R&D) expenses represent the costs incurred by a company in developing new products, services, or processes.
ABBV R&D Expense Chart
Current R&D Expense
$9.10B
$9.10 Billion
Year-over-Year Change
-28.89%
vs. $12.79B prior year
Historical Data
17
Years of data available
Annual R&D Expense History
| Year | R&D Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $9.10B | $-3.69B | -28.89% |
| 2024 | $12.79B | +$5.12B | +66.66% |
| 2023 | $7.67B | +$1.17B | +17.90% |
| 2022 | $6.51B | $-1.54B | -19.09% |
| 2021 | $8.05B | +$291.00M | +3.75% |
| 2020 | $7.75B | +$963.00M | +14.18% |
| 2019 | $6.79B | $-3.96B | -36.84% |
| 2018 | $10.75B | +$5.42B | +101.59% |
| 2017 | $5.33B | +$749.00M | +16.34% |
| 2016 | $4.58B | +$150.00M | +3.38% |
| 2015 | $4.43B | +$786.00M | +21.54% |
| 2014 | $3.65B | +$456.00M | +14.28% |
| 2013 | $3.19B | +$127.00M | +4.14% |
| 2012 | $3.07B | $-225.00M | -6.84% |
| 2011 | $3.29B | +$483.00M | +17.20% |
| 2010 | $2.81B | +$1.10B | +64.46% |
| 2009 | $1.71B | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael